Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma

This study is looking at real-world outcomes for patients with a type of liver cancer called intrahepatic cholangiocarcinoma (bile duct cancer inside the liver). Researchers want to understand how well different treatment combinations work — including chemotherapy alone versus chemotherapy combined with immunotherapy and targeted therapy drugs. **You may be eligible if...** - You have been diagnosed with intrahepatic cholangiocarcinoma (confirmed by tissue or imaging) - You were initially treated with GP or GEMOX chemotherapy, with or without additional immunotherapy (PD-1/L1 inhibitors) and targeted drugs (TKI inhibitors) **You may NOT be eligible if...** - You went directly to surgery after being admitted to the hospital - Your initial treatment included local therapies like radiation, radiofrequency ablation, particle implants, or a procedure called TACE - You received other combination treatment regimens not listed above Talk to your doctor to see if this trial is right for you.